Company profile: Vaxess
1.1 - Company Overview
Company description
- Provider of needle-free vaccine and therapeutic delivery solutions, offering the MIMIX applicator with patch for skin-based administration and silk fibroin biomaterials that create stable, biocompatible delivery systems, with a focus on improving access to vaccines.
Products and services
- Biomedical Innovation Development: Accessibility-focused R&D that develops biomedical innovations to improve access to vaccines, enhancing user experience in vaccine delivery
- MIMIX™ applicator with patch: Needle-free transdermal patch-and-applicator assembly that delivers vaccines and therapeutics through skin, enhancing accessibility and user experience via an easy-to-use format
- Silk Fibroin Biomaterials: Biocompatible biomaterials derived from silk proteins and engineered to create stable delivery systems for vaccines and therapeutics, enabling stability and biocompatibility in delivery
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Vaxess
MDNA Life Sciences
HQ: United States
Website
- Description: Provider of proprietary, blood-based diagnostic tests leveraging mitochondrial DNA to improve early disease detection, diagnosis, treatment, prognosis and monitoring. Offerings include the Mitomic Prostate Test (3.4 kb deletion to assess significant prostate cancer risk and aid biopsy decisions) and Mitomic Endometriosis Test (8.7 kb deletion to reduce diagnostic delays), powered by Mitomic Technology to detect disease-specific mtDNA biomarkers with high sensitivity and specificity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MDNA Life Sciences company profile →
Medical Prognosis Institute
HQ: Denmark
Website
- Description: Provider of drug targeting, pharmaco Dx, and DNA microarray services for research projects in Denmark, supporting drug development, individual cancer prognostication and drug sensitivity prediction, and gene/drug discovery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medical Prognosis Institute company profile →
IsoPlexis
HQ: United States
Website
- Description: Provider of single-cell detection technology that identifies a wide range of patient immune responses at the single-cell level. Its platform assesses the safety and efficacy of therapeutics and monitors disease progression to support improved therapeutic development and inform physician decisions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IsoPlexis company profile →
Totient
HQ: United States
Website
- Description: Provider of AI-driven biotechnology leveraging tertiary lymphoid structures to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics, using machine learning and immunoinformatics to pull critical insights from large, complex datasets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Totient company profile →
Precirix
HQ: Belgium
Website
- Description: Provider of radio-immunotherapeutic drugs for cancer patients, developing single-domain antibody CAM-H2 targeting HER2 combined with iodine-131 in Phase I/II for HER2-positive metastatic breast, gastric, and gastroesophageal cancers; FAP-targeting radiopharmaceutical program entering clinical trials; and a theranostic approach using imaging to select patients before treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Precirix company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Vaxess
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Vaxess
2.2 - Growth funds investing in similar companies to Vaxess
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Vaxess
4.2 - Public trading comparable groups for Vaxess
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →